(NSO-01) Supporting the Shift: Inpatient Review of BCMA CAR-T Therapy in Multiple Myeloma Reveals Early Safety and Feasibility for a Nurse Lead Outpatient Model of Care
(OA-13) Post-Induction Outcomes and Updated Minimal Residual Disease Analysis from GMMG-HD10/DSMM-XX (MajesTEC-5): A Study of Teclistamab-Based Induction Regimens in Newly Diagnosed Multiple Myeloma (NDMM)
Location: Room 701
Abstract Presenter: Marc S. Raab, MD PhD (he/him/his) – Dept. of Medicine V Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany
Cellular and T cell engager Immunotherapy
Wednesday, Sep 17th
11:10 - 11:20 East Coast USA Time
(OA-14) Cevostamab Plus Pomalidomide (Pom) and Dexamethasone (dex) in Relapsed/Refractory Multiple Myeloma (RRMM): Phase I Dose-Expansion Results from the CAMMA 1 Study
(OA-07) Elranatamab in Combination With Daratumumab and Lenalidomide (EDR) in Patients With Newly Diagnosed Multiple Myeloma (NDMM) Not Eligible for Transplant: Initial Results from MagnetisMM-6 Part 1
Location: Room 701
Abstract Presenter: Suzanne Trudel, MD – Princess Margaret Cancer Centre, Toronto, ON, Canada
Cellular and T cell engager Immunotherapy
Wednesday, Sep 17th
11:20 - 11:30 East Coast USA Time
(OA-10) MZB1-Directed HLA-Dependent CAR T Cells for Targeting B-Cell Malignancies
Location: Room 718
Abstract Presenter: Elena Maroto Martin, PhD (she/her/hers) – Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School
Cellular and T cell engager Immunotherapy
Wednesday, Sep 17th
11:30 - 11:40 East Coast USA Time
(OA-02) Sustained Remission After Limited-Duration of Bispecific Antibody Therapy in Patients with Relapsed/Refractory Multiple Myeloma
Location: Room 701
Abstract Presenter: Meera Mohan, MD – Medical College of Wisconsin
Cellular and T cell engager Immunotherapy
Wednesday, Sep 17th
11:30 - 11:40 East Coast USA Time
(OA-15) S100A8/A9 Promotes T Cell Exhaustion and Impairs Response to Bispecific Therapy in Multiple Myeloma
(PA-064) Linvoseltamab (LINVO) + Carfilzomib (CFZ) in Patients ( pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Initial Results from the LINKERMM2 Trial
Location: Room 714A
Abstract Presenter: Salomon Manier, MD, PhD – Hematology Department, Lille University Hospital, Lille, France
Cellular and T cell engager Immunotherapy
Thursday, Sep 18th
14:52 - 15:00 East Coast USA Time
(OA-67) Phase 2 Study of Cevostamab Consolidation Following BCMA CAR T Cell Therapy: Preliminary Safety and Efficacy Data from the “STEM” (Sequential T Cell-Engagement for Myeloma) Trial
Location: Hall FG
Abstract Presenter: Adam D. Cohen, MD – Perelman School of Medicine, University of Pennsylvania
Cellular and T cell engager Immunotherapy
Thursday, Sep 18th
15:00 - 15:08 East Coast USA Time
(OA-65) Farorable Outcome of Relapsed/Refractory Multiple Myeloma treated with Idecabtagene Vicleucel (Ide-cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy; IFM experience from the Descar-T Registry
(OA-01) TET2 and EZH2 Genetic Alterations Promote Malignant CAR-T Transformation in Anti-BCMA CAR-T Therapy
Location: Room 718
Abstract Presenter: Adolfo Aleman, PhD – Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai
Cellular and T cell engager Immunotherapy
Thursday, Sep 18th
16:00 - 16:10 East Coast USA Time
(OA-08) Three-Year Follow-Up of FUMANBA-1: a Phase 1b/ 2 Study of Fully Human Anti-BCMA CAR-T Equecabtagene Autoleucel in Patients with Relapsed/Refractory Multiple Myeloma
Location: Room 701
Abstract Presenter: Lugui Qiu, MD (he/him/his) – Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences.
Cellular and T cell engager Immunotherapy
Thursday, Sep 18th
16:10 - 16:20 East Coast USA Time
(OA-09) A Syngeneic Mouse Model of CAR-T Cell Therapy Containing a Translatable Dual Human/Mouse Reactive sdAb Binder in Vk*MYC Mice Reveals Clinically-Relevant Microenvironment Changes
(OA-03) Development and Validation of the SCOPE-MM Score: A Pre-Apheresis Risk Model Predicting Response and Toxicity in RRMM Patients Receiving BCMA-Directed CAR-T Therapy
(OA-06) Inactivation of TRAF3 and CYLD Drive Resistance to T-Cell Based Therapies in Multiple Myeloma by Promoting Inflammation and an Immunosuppressive Microenvironment that Impair T Cell Function
(OA-71) Concurrent Administration of BCMA and GPRC5D Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Relapsed or Refractory Multiple Myeloma: Results from the Phase I TANDEMM Clinical Trial
(PA-080) Arlocabtagene autoleucel, a GPRC5D-Targeted CAR T-Cell Therapy for Patients With Relapsed/Refractory Multiple Myeloma: Updated Phase 1 Safety and Efficacy Results in Patients With 1–3 Prior Regimens
Location: Room 714A
Abstract Presenter: Omar Nadeem, MD – Dana-Farber Cancer Institute
Cellular and T cell engager Immunotherapy
Friday, Sep 19th
12:23 - 12:29 East Coast USA Time
(PA-517) BCMA CAR-T Therapy with Radiotherapy Bridging and Maintenance Achieves Unprecedented Complete Response in Extramedullary Myeloma
(OA-16) BCMA CAR T-Cell Therapy in Newly Diagnosed Primary Plasma Cell Leukemia Ineligible for Transplantation: An Open Label, Single-arm, Phase 2 Study (CAREMM-002)
(OA-68) Safety and Efficacy of Linvoseltamab (LINVO) in Patients (Pts) with High-risk Smoldering Multiple Myeloma (HR-SMM): First Results from the Phase 2 LINKER-SMM1 Trial
